For example, CRC organoids with Kras mutation are resistant to the combination targeted inhibitors of EGF receptor (EGFR) and mitogen-activated protein kinase (MEK) [134] but showed promising viability inhibition upon tested with new combinations of trametinib, neratinib, and trastuzumab [135]. The gene discussed is KRAS; the disease is colorectal carcinoma.